Effects of neoadjuvant and adjuvant chemotherapy on survival in muscle-invasive bladder cancer: A multicenter study

Aim: Muscle-invasive bladder cancer requires systemic treatment due to its high risk of metastasis. However, studies comparing neoadjuvant and adjuvant therapy regimens are currently limited. Our goal in this study was to compare the treatment efficacy of patients receiving neoadjuvant or adjuvant treatment in locally advanced bladder cancer. Material and Methods: We retrospectively included 107 bladder cancer patients from 6 centres who underwent radical cystectomy and received perioperative chemotherapy. Patients were divided into 2 categories: (i) neoadjuvant chemotherapy (n=54) and (ii) adjuvant chemotherapy (n=53). Results: Median follow-up was 31.6 months (95%CI 21.8-41.4). 30-month disease-free survival (DFS) was 58.9% in the whole group, 56.3% in neoadjuvant and 61.5% in adjuvant. 30-month DFS after neoadjuvant treatment was 70.1% in

Authors

Institutions

Publication Details

Journal
Turkish Journal of Clinics and Laboratory
Published
2025-03-25
DOI
https://doi.org/10.18663/tjcl.1575691
Primary Topic
Bladder and Urothelial Cancer Treatments
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Effects of neoadjuvant and adjuvant chemotherapy on survival in muscle-invasive bladder cancer: A multicenter study

İbrahim Vedat Bayoğlu, Selver Işık, Osman Köstek, Nargız Majidova et al.
Turkish Journal of Clinics and Laboratory
Bladder and Urothelial Cancer Treatments
article

Effects of neoadjuvant and adjuvant chemotherapy on survival in muscle-invasive bladder cancer: A multicenter study

İbrahim Vedat Bayoğlu, Selver Işık, Osman Köstek, Nargız Majidova, Pınar Erel, Rukiye Arıkan, Sevdenur Taşkın, Ali Kaan Güren, Abdüssamet Çelebi, S. Seber, Murat Sarı, Murat Arcagök, Rumeysa Çolak, Zuhat Urakçı, Yeşim Ağyol, Erkam Kocaaslan, Özge Yalıcı, Ahmet Emin Öztürk, Yaprak Ḉaḡlar, Mehmet Cihan İcli̇, Nadiye Sever, Barış Köksal
article en

Abstract

Aim: Muscle-invasive bladder cancer requires systemic treatment due to its high risk of metastasis. However, studies comparing neoadjuvant and adjuvant therapy regimens are currently limited. Our goal in this study was to compare the treatment efficacy of patients receiving neoadjuvant or adjuvant treatment in locally advanced bladder cancer. Material and Methods: We retrospectively included 107 bladder cancer patients from 6 centres who underwent radical cystectomy and received perioperative chemotherapy. Patients were divided into 2 categories: (i) neoadjuvant chemotherapy (n=54) and (ii) adjuvant chemotherapy (n=53). Results: Median follow-up was 31.6 months (95%CI 21.8-41.4). 30-month disease-free survival (DFS) was 58.9% in the whole group, 56.3% in neoadjuvant and 61.5% in adjuvant. 30-month DFS after neoadjuvant treatment was 70.1% in

Turkish Journal of Clinics and LaboratoryVol. 16(1)
Dicle University (TR), Tekirdağ Namık Kemal University (TR), Bakırköy Psychiatric Hospital (TR), University of Health Sciences (SO), Hacettepe University (TR), Marmara University (TR)
Openalex Percentile: Top 91%
Bladder and Urothelial Cancer Treatments
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.